ADAPAdaptimmune Therapeutics PLC

Nasdaq adaptimmune.com


$ 1.22 $ 0.09 (7.83 %)    

Wednesday, 15-May-2024 15:59:26 EDT
QQQ $ 452.83 $ 6.97 (1.56 %)
DIA $ 399.31 $ 3.70 (0.94 %)
SPY $ 529.09 $ 6.48 (1.24 %)
TLT $ 92.14 $ 1.24 (1.36 %)
GLD $ 220.89 $ 2.80 (1.28 %)
$ 1.24
$ 1.25
$ 0.00 x 0
$ 0.00 x 0
$ 1.13 - $ 1.25
$ 0.42 - $ 2.05
1,417,397
na
316.9M
$ 1.87
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-06-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-06-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-14-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-01-2019 06-30-2019 10-Q
21 05-06-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 03-15-2018 12-31-2017 10-K
27 11-02-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-13-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-08-2016 06-30-2016 10-Q
33 05-12-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 adaptimmune-therapeutics-q1-2024-gaap-eps-003-beats-009-estimate-sales-5678m-miss-10733m-estimate

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate...

 adaptimmune-therapeutics-says-on-april-10-unit-of-co-received-notice-of-termination-of-strategic-collaboration-and-license-agreement-with-genentech-termination-will-become-effective-180-days-after-date-of-receipt-as-result-of-termination-co-not-entitled-to-receive-further-milestones-or-other-payments-due-after-termination-date

-SEC Filing

 why-marvell-technology-shares-are-trading-lower-by-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quart...

 smith--wesson-brands-reports-upbeat-earnings-joins-americas-car-mart-hci-group-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday.

 adaptimmune-therapeutics-q4-eps-004-beats-010-estimate-sales-23100k-may-not-be-comparable-to-2047m-estimate

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate...

 earnings-scheduled-for-march-6-2024

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue o...

 adaptimmune-therapeutics-q3-eps-018-misses-015-estimate-sales-732m-miss-1028m-estimate

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.18) per share which missed the analyst consensus estima...

 earnings-scheduled-for-november-8-2023

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.

 adaptimmune-reports-better-outcomes-for-people-with-synovial-sarcoma-who-received-afami-cel-compared-to-historical-control

~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of respo...

 stocks-that-hit-52-week-lows-on-tuesday

  During Tuesday's session, 275 companies made new 52-week lows.

 stocks-that-hit-52-week-lows-on-friday

  Friday's session saw 225 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-thursday

  On Thursday, 283 companies set new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION